ADPKD
ADPKD
Part of NephTimes
Advertisement
Victoria SochaADPKD | June 26, 2025
The race of patients with ADPKD affects waitlist experience, allograft quality, and post-transplant outcomes, a study found.
Victoria SochaADPKD | June 26, 2025
A study of real-world data found that tolvaptan reduced long-term kidney function decline in ADPKD.
Freely FilteredADPKD | June 11, 2025
This Freely Filtered episode discusses the KDIGO guideline draft for autosomal dominant polycystic kidney disease (ADPKD).
Charlotte RobinsonADPKD | May 2, 2025
Novartis will acquire Regulus Therapeutics, developer of ADPKD therapeutic candidate farabursen, a novel oligonucleotide.
Charlotte RobinsonADPKD | June 13, 2025
Lupin's generic tolvaptan tablets are now FDA-approved for treating autosomal dominant polycystic kidney disease (ADPKD).
Victoria SochaNKF Spring Clinical Meetings 2025 | July 7, 2025
A study examined the effects of SGLT2i on eGFR slope in patients with autosomal dominant polycystic kidney disease.
Charlotte RobinsonADPKD | June 13, 2025
KDIGO has published its first guideline on the evaluation, management, and treatment of ADPKD.
Victoria SochaADPKD | June 13, 2025
A study examined the effects of adding dapagliflozin to treatment with tolvaptan in patients with ADPKD.
Charlotte RobinsonADPKD | June 13, 2025
A study examined whether serum phosphate levels could predict kidney outcomes in patients with ADPKD. 
Charlotte RobinsonADPKD | June 13, 2025
An exploratory pilot study aimed to identify and evaluate potential proinflammatory biomarkers in patients with ADPKD.
Charlotte RobinsonASN Kidney Week 2024 | June 23, 2025
RGLS8429 increases urinary PC1 and PC2 proteins, which may help reduce height-adjusted total kidney volume in ADPKD.
Charlotte RobinsonASN Kidney Week 2024 | June 23, 2025
Could pravastatin slow the rate of increase in height-adjusted total kidney volume in adults with ADPKD?
Charlotte RobinsonASN Kidney Week 2024 | June 23, 2025
Researchers assessed the safety and efficacy of bardoxolone methyl (BARD) in patients with ADPKD.
Victoria SochaASN Kidney Week 2024 | June 23, 2025
Recent research reveals tolvaptan’s role in reducing hemodialysis initiation risk in ADPKD,
Victoria SochaASN Kidney Week 2024 | June 23, 2025
A study examined physician confidence and barriers to prescription of tolvaptan for the management of ADPKD.
Victoria SochaASN Kidney Week 2024 | June 23, 2025
A study investigated whether treatment with difelikefalin and tolvaptan can protect against worsening of late-stage PKD.
Victoria SochaASN Kidney Week 2024 | June 23, 2025
ESSENTIAL assessed the safety and effectiveness of tolvaptan among patients in Korea with ADPKD and CKD stages 1 to 3.
Victoria SochaASN Kidney Week 2024 | June 23, 2025
Tolvaptan increased serum sodium without causing sodium overcorrection in syndrome of inappropriate antidiuresis.
Charlotte RobinsonADPKD | June 13, 2025
A post hoc analysis of TEMPO 3:4 results examined longer-term effects of tolvaptan on TKV and eGFR in patients with ADPKD.
Charlotte RobinsonADPKD | June 13, 2025
Data regarding mortality specific to patients with autosomal dominant polycystic kidney disease (ADPKD) are limited.
Advertisement